SCHEMBL122394

SCHEMBL122394

CC1(c2cnccn2)CO1

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.36
HSP90AA1 P07900 1/20 0.33
SLC6A2 P23975 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18248471 0.76 KIF11 (0.30) KIF11
SCHEMBL10387750 0.75 KIF11 (0.31) KIF11HSP90AA1
SCHEMBL19399263 0.74 HSP90AA1 (0.36) KIF11HSP90AA1
SCHEMBL12479829 0.71 SLC6A2 (0.50) KIF11SLC6A2
SCHEMBL24087839 0.71 HSP90AA1 (0.33) KIF11HSP90AA1
SCHEMBL20508939 0.71 HSP90AA1 (0.33) KIF11HSP90AA1
SCHEMBL19779256 0.69 HSP90AA1 (0.37) HSP90AA1
SCHEMBL1828930 0.69 KIF11 (0.35) KIF11HSP90AA1
SCHEMBL118017 0.69 HSP90AA1 (0.35) HSP90AA1
SCHEMBL22772556 0.68 KIF11 (0.35) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9255094-B2 Pyrido[4,3-B]indoles and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2016-02-09 US disclosed
US-20130190328-A1 PYRIDO[4,3-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2013-07-25 US disclosed
US-20120136008-A1 PYRIDO[4,3-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2012-05-31 US disclosed
EP-2424364-A1 PYRIDO [4,3-B] INDOLES AND METHODS OF USE Medivation Technologies, Inc. (US) 2012-03-07 EP disclosed
WO-2010127177-A1 PYRIDO [4,3-B] INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190328-A1 PYRIDO[4,3-B]INDOLES AND METHODS OF USE HTR3B, HTR4, HTR2C KIF11 2964/4885HSP90AA1 4591/4885SLC6A2 144/4885
US-20120136008-A1 PYRIDO[4,3-B]INDOLES AND METHODS OF USE HTR3B, HTR4, HTR2C KIF11 2964/4885HSP90AA1 4591/4885SLC6A2 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.